# Fibulin-3 is a Novel TGF-β pathway Inhibitor in the Breast Cancer Microenvironment

**Hongyu Tian**[1], **Jiangxin Liu**[2,3], **Jian Chen**[1], **Michael L. Gatza**[4], and **Gerard C. Blobe**[1,5]

[1]Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham NC 27710

[2]Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

[3]State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, P. R. China

[4]University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill NC 27599

[5]Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham NC 27708

## Abstract

TGF-β is an important regulator of breast cancer progression. However, how the breast cancer microenvironment regulates TGF-β signaling during breast cancer progression remains largely unknown. Here, we identified fibulin-3 as a secreted protein in the breast cancer microenvironment, which efficiently inhibits TGF-β signaling in both breast cancer cells and endothelial cells. Mechanistically, fibulin-3 interacts with the type I TGF-β receptor (TβRI) to block TGF-β induced complex formation of TβRI with the type II TGF-β receptor (TβRII) and subsequent downstream TGF-β signaling. Fibulin-3 expression decreases during breast cancer progression, with low fibulin-3 levels correlating with a poorer prognosis. Functionally, high fibulin-3 levels inhibited TGF-β-induced EMT, migration, invasion and endothelial permeability, while loss of fibulin-3 expression/function promoted these TGF-β-mediated effects. Further, restoring fibulin-3 expression in breast cancer cells inhibited TGF-β signaling, breast cancer cell EMT, invasion and metastasis *in vivo*. These studies provide a novel mechanism for how TGF-β signaling is regulated by the tumor microenvironment, and provide insight into targeting the TGF-β signaling pathway in human breast cancer patients.

## Introduction

Breast cancer is the most common cancer among American women, with 12% of American women developing invasive breast cancer during their lifetime. Worldwide, breast cancer

Corresponding Author: Gerard C. Blobe, Dept. of Medicine, Duke University Medical Center, B354 LSRC, Box 91004 DUMC, Durham, NC 27708, Phone: (919)-668-1352, Fax: (919)-681-6906, gerard.blobe@duke.edu.

**Conflict of interest:** No potential conflicts of interest were disclosed.

accounts for 22.9% of invasive cancers in women, with 425,000 women dying of breast cancer each year, underscoring the need to define mechanisms of breast cancer initiation and progression.

Cytokines and growth factors, including the transforming growth factor-β (TGF-β) superfamily, have important roles in breast cancer initiation and progression[1–4]. TGF-β is a prototypic family member of 33 secreted structurally related cytokines, including TGF-β, activin, nodal, and bone morphogenetic proteins (BMPs). TGF-β signaling has dual roles during breast cancer progression[5–7]. In normal breast tissue and during the early stages of breast cancer initiation, the TGF-β signaling pathway functions as a tumor suppressor via suppressing proliferation, while promoting differentiation and apoptosis. However, in the later stages of breast cancer progression, the TGF-β signaling pathway acts as a tumor promoter, driving cell migration, invasion and metastasis, at least in part, via inducing epithelial-mesenchymal transition (EMT). The dual roles of the TGF-β signaling pathway during breast cancer progression suggest tight control and regulation of this pathway during breast cancer progression.

The canonical TGF-β superfamily signaling pathway is triggered when TGF-β superfamily ligands bind to cell surface receptors, including co-receptors, type II, and type I receptors. Upon ligand binding, these receptors form complexes, which facilitate the transphosphorylation and activation of TβRI by TβRII; the TβRI then phosphorylates receptor-regulated Smads (R-Smads), which bind the co-Smad, Smad4, and accumulate in the nucleus where they act in concert with co-activators and co-repressors to regulate target gene expression[8–14]. Although mechanisms by which TGF-β signaling is regulated by the cellular machinery is widely and extensively studied[5, 6, 15–18], how the breast cancer microenvironment, which has important roles in mediating breast cancer progression[19–21], regulates TGF-β signaling during breast cancer progression remains largely unknown.

The breast and breast cancer microenvironment consists of extracellular matrix (ECM), stromal cells (e.g. endothelial cells, fibroblasts, myofibroblasts and leukocytes), and cytokines, chemokine and proteins secreted by breast epithelial, breast cancer or stromal cells[22]. Both cell-cell and cell-microenvironment interactions modify the proliferation, survival, polarity, differentiation and invasive capacity of mammary epithelial cells. Most of these effects are mediated by these secreted proteins, including TGF-β superfamily cytokines[23–25]. In addition to cytokines, secreted proteins[21, 26,27] and exosomes[28–30] can cooperate or regulate these cytokines to control breast cancer progression. Indeed, we have previously established that decreases in shed soluble type III TGF-β receptor (sTβRIII) increases TGF-β signaling in the tumor microenvironment to generate an immunotolerant tumor microenvironment in breast cancer[26], and promote breast cancer metastasis[27]. In addition, the secreted protein Coco was recently demonstrated to inhibit BMP signaling to reactivate dormant breast cancer lung micrometastasis[31]. However, how secreted proteins in the breast cancer microenvironment regulate breast cancer progression still remains poorly understood.

The fibulins are a family of secreted proteins that associate with the extracellular matrix (ECM) scaffold, forming anchoring structures that can regulate cell proliferation and

migration[32–34]. Seven fibulin family members have been identified, with family members defined by the presence of two structural modules, a tandem repeat of epidermal growth factor-like modules and a unique C-terminal fibulin-type module. The FBLN-3 gene (also called EFEMP1) encodes fibulin-3, and is a relatively recent addition to the family. Fibulin-3 has been reported to be downregulated in several solid tumors[35], including breast cancer, via aberrant promoter methylation[36–38], with loss of fibulin-3 expression associated with tumor progression, metastasis and a poor patient prognosis. Although fibulin-3 has been reported to regulate some signaling pathways including the MAPK[7], Akt[7, 39] Notch[40] and Wnt[41] signaling pathways, the role of fibulin-3 in the TGF-β signaling pathway has not been investigated. Here we utilize a proteomic approach to investigate the role of secreted proteins in regulating TGF-β signaling in the breast cancer tumor microenvironment.

## Results

### Conditioned media from breast cancer cells inhibits TGF-β signaling

To investigate whether there were components in the breast cancer microenvironment which regulate TGF-β signaling, we examined the effects of conditioned media from the estrogen receptor negative human breast cancer cell line, MDA-MD-231 cells, on TGF-β and BMP2 signaling. Pretreating MDA-MB-231 cells with conditioned media dramatically inhibited TGF-β induced Smad2 phosphorylation and AKT phosphorylation (Fig. 1A), while only slightly inhibiting BMP-2 induced Smad1/5/8 phosphorylation (Fig. 1B). As stromal cells, including endothelial and immune cells, interact and regulate breast cancer cells, we next asked whether the breast cancer conditioned media also regulates TGF-β signaling in endothelial cells. Pretreating human microvascular endothelial cells (HMEC-1) with MDA-MB-231 conditioned media inhibited TGF-β induced Smad1/5/8 phosphorylation, increased basal Smad2 phosphorylation, inhibited TGF-β induced Smad2 phosphorylation (Fig. 1C) and TGF-β induced transcription of its downstream genes, including Smad7 and plasminogen activator inhibitor-1 (PAI-1) (Fig. 1D). However, MDA-MB-231 conditioned media had no effect on BMP-9 signaling in endothelial cells (Fig. 1C, 1D). In addition, the conditioned media from the estrogen receptor positive human breast cancer line, MCF-7, also inhibited TGF-β induced Smad1/5/8 phosphorylation in a dose dependent manner in HMEC-1 cells (Supplementary Fig. 1A). However, only high doses of conditioned media increased basal Smad2 phosphorylation, while inhibiting TGF-β induced Smad2 phosphorylation in HMEC-1 cells (Supplementary Fig. 1A), and having no effect on BMP-9 signaling (Supplementary Fig. 1B). These results suggest that there are active components in the conditioned media from breast cancer cells that inhibit TGF-β signaling, without effecting BMP-9 signaling.

As the overall effect of conditioned media from breast cancer cells integrates the effects of secreted TGF-β ligands, TGF-β activators and repressors, to identify the active components responsible for inhibiting TGF-β signaling, the conditioned media from MDA-MB-231 cells was fractionated using FPLC gel filtration (Supplementary Fig. 1C) and the fractions screened for inhibitory activity. The eluted fractions were combined into groups based on their elution peaks (Supplementary Fig. 1C) and used to pretreat HMEC-1 cells. Compared to the other combined fractions, fractions 17–26 inhibited TGF-β induced Smad1/5/8 and

Smad2 phosphorylation (Supplementary Fig. 1D). Further, individual fractions 17, 18, 19 and 20 inhibited TGF-β induced Smad2 phosphorylation (Fig. 1E), suggesting these fractions contained the active components responsible for mediating inhibition of TGF-β signaling. The proteins in fractions, and their adjacent fractions, were resolved by SDS-PAGE and detected by silver nitrate staining (Supplementary Fig. 1E). The two bands that were enriched in fractions 17–20 relative to adjacent fractions were cut out and subjected to mass spectrometry analysis, resulting in the identification of 15 candidate proteins (Supplementary Table 1).

## Fibulin-3 is the active component that inhibits TGF-β signaling

Three of the identified candidates proteins were secreted proteins (Supplementary Table 1), including EGF-containing fibulin-like extracellular matrix protein 1 (fibulin-3, FBLN3), serum albumin, and transforming growth factor-beta-induced protein ig-h3 (βIGH3). As exogenous serum albumin did not regulate TGF-β induced Smad2 phosphorylation in MDA-MB-231 cells (Supplementary Fig. 2A), and decreasing βIGH3 levels in MDA-MB-231 conditioned media by either immunodepletion (Supplementary Fig. 2B) or stable knockdown (Supplementary Fig. 2C, 2D) further decreased TGF-β induced Smad1/2/5/8 phosphorylation in HMEC-1 cells (Supplementary Fig. 2B and 2E), we turned our attention to fibulin-3, which has been demonstrated to regulate other signaling pathways[7, 39, 40]. As MDA-MB-231 cells express and secrete high levels of fibulin-3 (Fig. 4H, Supplementary Fig. 2H), we used shRNA to stably silence fibulin-3 expression and secretion (Supplementary Fig. 2F-H) in MDA-MB-231 cells (shFBLN3-MDA-MB-231), with a non-targeted shRNA control (shNTC-MDA-MB-231). In the presence of blank medium, TGF-β induced Smad2 phosphorylation in both shNTC-MDA-MB-231 and shFBLN3-MDA-MB-231 cells (Fig. 2A). However, consistent with our prior results, conditioned media from shNTC-MDA-MB-231 cells inhibited TGF-β induced Smad2 phosphorylation (Fig. 2A, Supplementary Fig. 2L) and TGF-β-induced transcription of its downstream genes, Smad7 (Fig. 2B) and PAI-1 (Fig. 2C), while conditioned media from shFBLN3-MDA-MD-231 cells failed to inhibit TGF-β induced Smad2 phosphorylation (Fig. 2A) or TGF-β induced Smad7 (Fig. 2B) or PAI-1 (Fig. 2C) transcription. Similarly, conditioned media from shFBLN3-MDA-MD-231 cells did not inhibit TGF-β induced Smad1/5/8 and Smad2 phosphorylation in HMEC-1 cells (Fig. 2D) or in colon fibroblast 18Co cells (Supplementary Fig. 2I). Further, MDA-MB-231 conditioned media immunodepleted with two different anti-fibulin-3 antibodies did not inhibit TGF-β induced Smad1/2/5/8 phosphorylation (Fig. 2E, Supplementary Fig. 2J). In a reciprocal manner, the highly metastatic MDA-MB-231-4175 subline expressed and secreted low levels of fibulin-3 (Fig. 4H, Supplementary Fig. 2H), and as expected, its conditioned media did not inhibit TGF-β induced Smad phosphorylation or Smad7 and PAI-1 transcription in MDA-MA-MB-231-4175 (Fig. 2F, 2G, 2H, Supplementary Fig. 2L) or HMEC-1 cells (Fig. 2I). However, the conditioned media from MDA-MB-231-4175 cells stably overexpressing fibulin-3 (Supplementary Fig. 2H, 2K) inhibited TGF-β signaling (Fig. 2F, 2I) and TGF-β induced genes transcription (Fig. 2G, 2H). Moreover, exogenous fibulin-3 inhibited TGF-β induced Smad1/2/5/8 phosphorylation and Smad7 and PAI-1 transcription in HMEC-1 cells (Fig. 2J) and in MDA-MB-231 cells (Figs. 3A, 2K, 2L). In addition, pretreating MDA-MB-231 cells with recombinant fibulin-3 also inhibited TGF-β induced p38 phosphorylation

(Supplementary Fig. 2M). Consistent with the previous report[7], fibulin-3 increased basal AKT and ERK1/2 phosphorylation, while inhibiting TGF-β induced AKT and ERK1/2 phosphorylation (Supplementary Fig. 2M). As fibulin-3 inhibits lung cancer metastasis via suppressing the ERK-Wnt/β-catenin signaling axis[41], we test whether fibulin-3 inhibits this pathway in breast cancer cells. Knockdown of fibulin-3 had no effect on β-catenin nuclear translocation (Supplementary Fig. 2N) and ERK phosphorylation (Supplementary Fig. 2O). Taken together, these data indicate that fibulin-3 is the active component in the breast cancer secretome that inhibits both canonical and non-canonical TGF-β signaling in breast cancer epithelial cells, endothelial cells and fibroblasts.

## Fibulin-3 inhibits TGF-β signaling via interaction with TβRI to decrease TβRI/TβRII complex formation

Having defined fibulin-3 as an inhibitor of TGF-β signaling, we turned our attention to defining the mechanism by which fibulin-3 inhibits TGF-β signaling. Fibulin-3-mediated inhibition of TGF-β signaling did not require protein synthesis or degradation, as pretreating cells with the protein synthesis inhibitor, cycloheximide, the proteasome inhibitor, MG132, or the lysosomal cysteine protease inhibitor, leupeptin, did not diminish the effect of conditioned media in inhibiting TGF-β signaling (Supplementary Fig. 3A, 3B). We next assessed whether fibulin-3 inhibits TGF-β signaling by binding and sequestering TGF-β ligand. Compared with soluble TβRIII, which, as expected, efficiently bound TGF-β[27], fibulin-3 did not directly bind TGF-β1 (Supplementary Fig. 3C).

To investigate whether fibulin-3 inhibited TGF-β induced Smad2 phosphorylation upstream or downstream of TβRI, we investigated the effects of exogeneous fibulin-3 on ligand versus constitutively activated TβRI induced Smad2 phosphorylation. While exogeneous fibulin-3 inhibited TGF-β ligand induced Smad2 phosphorylation, it did not inhibit constitutively activated TβRI mediated phosphorylation of Smad2 (Fig. 3A), suggesting that fibulin-3 inhibits TGF-β signaling upstream of TβRI activation. As fibulin-3 binds with receptors from other families, including the EGF receptor[7], we tested whether fibulin-3 could form complexes with TGF-β receptors, including TβRI and TβRII, to potentially inhibit TβRI activation. TβRI, and to a lesser extent for TβRII, co-immunoprecipitated with fibulin-3 in COS7 cells co-expressing fibulin-3 and TβRI or TβRII (Fig. 3B). In a reciprocal manner, fibulin-3 also co-immunoprecipitated with TβRI but not TβRII (Fig. 3C). Further, purified recombinant fibulin-3 co-immunoprecipitated with TβRI but not TβRII (Fig. 3D). As fibulin-3 is a secreted protein, we expressed and purified cellular HA-TβRI and HA-TβRII from COS7 cells using anti-HA beads, and tested whether TβRI or TβRII formed a complex with fibulin-3 in the conditioned media. HA-TβRI, but not TβRII formed a higher molecular weight complex with fibulin-3 (Supplementary Fig. 3D), suggesting that fibulin-3 may inhibit TGF-β signaling through interaction with TβRI.

We then investigated whether the interaction between fibulin-3 and TβRI blocked TGF-β induced TβRI/TβRII complex formation, which is an essential step for downstream TGF-β signaling[11, 42, 43]. While conditioned media from control MDA-MB-231 cells (Fig. 3E) or recombinant fibulin-3 (Supplementary Fig. 3E) inhibited TGF-β-induced TβRI/TβRII complex formation, conditioned media from shFBLN3-MDA-MB-231 cells failed to inhibit

TGF-β induced TβRI/TβRII complex formation (Fig. 3E). Finally, as the TGF-β signaling pathway is subject to multiple levels of regulation, we assessed the effects of TGF-β on fibulin-3 levels. TGF-β induced fibulin-3 expression in a time dependent manner in both MDA-MB-231 cells and MDA-MB-231-4175 cells (Fig. 3F). Collectively, these data indicate that fibulin-3 inhibits TGF-β signaling in a negative feedback loop through interaction with TβRI to inhibit TβRI/TβRII complex formation (Fig. 8A).

## Fibulin-3 expression is decreased during breast cancer progression

Having identified fibulin-3 as a novel and key suppressor of TGF-β signaling in the breast cancer microenvironment, we next investigated whether fibulin-3 expression changes during breast cancer progression. In a meta-analysis of 32 publically available datasets on Oncomine, fibulin-3 expression was decreased in breast cancer compared to normal breast (Fig. 4A). Further, while normal mammary epithelial tissue expressed high levels of fibulin-3, human breast cancer orthotopic xenograft expressed very low levels of fibulin-3 (Fig. 4B). In addition, compared to normal breast, fibulin-3 levels were decreased in basal, Her2, luminal A and luminal B subtypes of breast cancers (Supplementary Fig. 4A), suggesting that decreased fibulin-3 expression is general feature of breast cancer progression. Moreover, relative to normal breast, fibulin-3 expression decreased beginning in Stage I breast cancer, with more pronounced decreases in stage IV breast cancer (Fig. 4C), and relative to pre-invasive ductal carcinoma in situ (DCIS), fibulin-3 expression decreased in both invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC, Fig. 4D). Further, low expression level of fibulin-3 correlated with worse survival in breast cancer patients (http://kmplot.com/analysis/) (Fig. 4E). These data support an important role for fibulin-3 in breast cancer progression. Consistent with this hypothesis, in the MCF10A breast cancer progression series[44], with MCF10A cells being non-tumorigenic, MCF10A-T1k cells forming hyperplastic lesions, MCF10A-CA1h cells forming low-grade, well-differentiated carcinomas and MCF10A-CA1a cells forming poorly differentiated, metastatic carcinomas, fibulin-3 mRNA levels progressively decreased with cancer progression (Fig. 4F). In addition, compared to the non-metastatic cell line, MCF10A-CA1h, fibulin-3 protein levels in the conditioned media were dramatically decreased in metastatic MCF10A-CA1a cells (Fig. 4G). Consistent with a prior report[45], fibulin-3 mRNA levels were also decreased in the metastatic MDA-MB-231-4175 subline compared with the poorly-metastatic parental MDA-MB-231 cells (Fig. 4H). In addition, in the isogenic murine mammary carcinoma progression series, composed of four murine mammary carcinoma cell lines (67NR, 168FARN, 4TO7 and 4T1), each with progressive metastatic potential but all derived from same parental breast tumor[46], fibulin-3 mRNA levels were decreased in metastatic 4T1 cells relative to the other nonmetastatic cells (Supplementary Fig. 4B). Thus, in all series, fibulin-3 expression was lost as cells acquired metastatic capability.

As the fibulin-3 promoter has CpG islands (Supplementary Fig. 4C) and has been reported to be regulated by promoter methylation[36–38], we investigated the potential for epigenetic regulation in our model systems. Treating 4T1 cells (Supplementary Fig. 4D) or MDA-MB-231-4175 cells (Supplementary Fig. 4E) with the promoter methylation inhibitor, 5-azacytidine, increased fibulin-3mRNA levels in both cell lines. These data suggest that

fibulin-3 expression is decreased via either direct or indirect epigenetic silencing during breast cancer progression.

## Decreased fibulin-3 promotes TGF-β induced epithelial-mesenchymal transition (EMT), migration and invasion *in vitro*

As fibulin-3 inhibits TGF-β signaling in breast cancer cells and fibulin-3 expression decreases during breast cancer progression, especially in invasive breast cancer and at the later stages of breast cancer progression, we next investigated the effects of fibulin-3 on TGF-β-induced migration and invasion. While conditioned media from poorly-metastatic parental MDA-MB-231 cells with high fibulin-3 expression[45] (Fig. 4H, Supplementary Fig. 2H) inhibited TGF-β induced migration (Fig. 5A, Supplementary Fig. 5A) and invasion (Fig. 5B), conditioned media from shFBLN3-MDA-MB-231 failed to inhibit TGF-β's effects (Fig. 5A, B). Although TGF-β was not able to induce migration in MDA-MB-231-4175 cells (Supplementary Fig. 5B), TGF-β induced their invasion (Fig. 5C), and conditioned media from MDA-MB-231-4175 cells with low fibulin-3 expression[45] (Fig. 4H, Supplementary Fig. 2H) was not able to inhibit TGF-β induced invasion (Fig. 5C). However, the conditioned media from MDA-MB-231-4175 stably overexpressing fibulin-3 inhibited TGF-β's effects (Fig. 5C), supporting that fibulin-3 mediated inhibition of TGF-β signaling is sufficient to block TGF-β functions during breast cancer progression. In addition, consistent with fibulin-3 having no effect on the ERK-Wnt signaling axis in breast cancer cells (Supplementary Fig. 2N, 2O), silencing fibulin-3 expression had no significant effects on MDA-MB-231 cell migration in the presence or absence of the Wnt pathway inhibitor, IWP-2, (Supplementary Fig. 5C).

As EMT is important for breast cancer metastasis and TGF-β is a strong EMT inducer, we next investigated whether decreased fibulin-3 promotes EMT by enhancing TGF-β signaling in normal mouse mammary epithelial cells (NMuMG), which have been widely used as an EMT model. TGF-β induced Smad2 phosphorylation (Fig. 5D) and EMT in blank medium as detected by changes in cell morphology (Fig. 5E) and EMT marker expression, including upregulation of fibronectin and downregulation of E-cadherin (Fig. 5F). While conditioned media from NMuMG cells decreased TGF-β induced Smad2 phosphorylation (Fig. 5D) and EMT (Fig. 5E, F), the conditioned media from shFBLN3-NMUMG cells was not able to inhibit TGF-β's effects (Fig. 5D, E, F). Consistent with an effect on EMT, fibulin-3 (Fig. 5G) and ZO-1 (Fig. 5H) mRNA levels decreased, with their expression positively correlating (TCGA data base: Q-value=2.6e-11; METABRIC database: Q-value=2.5e-02), while PAI-1, a TGF-β downstream gene (Fig. 5I), and fibronectin (Fig. 5J) mRNA levels increased in breast tumor tissue compared with their paired normal breast tissue in 92 normal-tumor pairs from the TCGA dataset. Collectively, these data indicate that decreased fibulin-3 expression during breast cancer progression may promote TGF-β induced breast cancer cell EMT, migration and invasion.

## Decreased fibulin-3 enhances TGF-β's effects on endothelial sprouting and transendothelial cell migration

As fibulin-3 inhibits TGF-β signaling in endothelial cells, we investigated fibulin-3's roles in endothelial biology. While conditioned media from metastatic MDA-MB-231-4175

cells[45] with very low fibulin-3 expression (Fig. 4H, Supplementary Fig. 2H) did not inhibit TGF-β-mediated decreases in sprouting as detected by spheroid-based sprout assay, the conditioned media from MDA-MB-231-4175 stably overexpressing fibulin-3 inhibited TGF-β-mediated decreases in sprouting (Fig. 6A and 6B). In addition, while TGF-β did not decrease sprouting in the conditioned media from poorly-metastatic parental MDA-MB-231 cells[45] with high fibulin-3 expression (Fig. 4H, Supplementary Fig. 2H), TGF-β decreased sprouting in the presence of conditioned media from shFBLN3-MDA-MB-231 cells (Fig. 6C).

As breast cancer cell intravasation into or extravasation out of blood vessels are pivotal steps for cancer metastasis, and both processes require transendothelial cell migration, we studied the effect of fibulin-3 on transendothelial cell migration. While TGF-β increased transendothelial cell migration in blank medium and in the conditioned media from metastatic MDA-MB-231-4175 cells (Fig. 6D, E) with very low fibulin-3 expression[45] (Fig. 4H, Supplementary Fig. 2H), conditioned media from MDA-MB-231-4175 cells stably expressing fibulin-3 (Fig. 6D, E) or from poorly-metastatic parental MDA-MB-231 cells (Fig. 6F) with high fibulin-3 expression[45] (Fig. 4H, Supplementary Fig. 2H) inhibited TGF-β-increased transendothelial cell migration (Fig. 6D, E and F), while conditioned media from MDA-MB-231-shFBLN3 cells restored TGF-β-increased transendothelial cell migration (Fig. 6F). These data indicate that decreased fibulin-3 promotes TGF-β regulation of endothelial sprouting and transendothelial cell migration to facilitate breast cancer metastasis.

### Overexpression of fibulin-3 inhibits breast cancer metastasis *in vivo*

To investigate whether the ability of fibulin-3 to inhibit TGF-β signaling in both breast cancer and endothelial cell function *in vitro* had effects on breast cancer progression *in vivo*, we injected MDA-MB-231-4175 stably expressing fibulin-3 into the inguinal mammary fat pads of nude mice. While there were no effects on primary tumor growth (Fig. 7A), fibulin-3 expression inhibited and delayed breast cancer metastasis (Fig. 7B, C). Further, fibulin-3 expression also inhibited micrometastasis to the liver as detecting by staining with anti-human vimentin (Fig. 2D). Expression of fibulin-3 also appeared to decrease cancer cell invasiveness *in vivo*, decreasing the extent to which MDA-MB-231-4175 cancer cells penetrated through smooth muscle layers (Black arrows, Fig. 7E). In addition, while the control MDA-MB-231-4175 cells displayed an elongated, mesenchymal-phenotype, fibulin-3 expression promoted a more cobble-stone epithelial morphology (Fig. 7F, G), and increased pan-cytokeratin and decreased fibronectin expression relative to control MDA-MB-231-4175 cells (Fig. 7G). Finally, fibulin-3 expressing MDA-MB-231-4175 tumors had reduced nuclear p-Smad2 staining relative to control MDA-MB-231-4175 tumors (Fig. 7H). Taken together, these data indicate that expression of fibulin-3 decreased TGF-β/Smad2 signaling and inhibited breast cancer EMT and metastasis *in vivo*.

## Discussion

Here, we used an unbiased approach to identify fibulin-3 as a novel and key regulator of the TGF-β signaling pathway in the breast cancer microenvironment (Fig. 8A). Fibulin-3

expression decreases during breast cancer progression, with decreased fibulin-3 promoting TGF-β signaling and in turn promoting EMT, migration, invasion and transendothelial cell migration of breast cancer cells (Fig. 8B). Mechanistically, fibulin-3 inhibits the TGF-β pathway through interaction with TβRI and inhibition of TGF-β induced TβRI/TβRII complex formation (Fig. 8A).

The TGF-β pathway is tightly regulated to have dual tumor suppressor and tumor promoter roles during breast cancer progression[5–7]. Although mechanisms regulating the TGF-β pathway within the cancer cell have been extensively studied, mechanisms by which the tumor microenvironment might regulate TGF-β signaling are less defined. Importantly, secreted proteins have the potential to coordinately regulate TGF-β signaling in the multiple different cell types represented in the tumor microenvironment, including cancer cells, endothelial cells, fibroblasts and immune cells. Here we identify fibulin-3 as one of those secreted proteins, which can inhibit TGF-β signaling in cancer cells, endothelial cells and fibroblast cells. Whether fibulin-3 also inhibits TGF-β signaling in other components of the tumor microenvironment, including immune system cells, to mediate its effects on inhibiting cancer progression remains to be explored. In addition, while the current studies focused on breast cancer, fibulin-3 expression is also decreased in other cancers[36, 47–49], suggesting that loss of fibulin-3 expression may be a common mechanism by which TGF-β signaling is increased to promote cancer progression.

In the context of breast cancer progression, the source, timing and mechanisms for loss of fibulin-3 expression is critical and of potential translational relevance. Fibulin-3 is ubiquitously expressed and secreted from all types of cells, including epithelial cells, endothelial cells and fibroblast cells. However, in the context of the breast cancer microenvironment, as breast cancer cells constitute the majority of cells, breast cancer cells are likely the major source of fibulin-3. Here we demonstrate that fibulin-3 expression decreases during breast cancer progression, particularly from breast cancer cells and in human breast cancer specimens, with this loss occurring primarily as the breast cancer cell acquires invasive capabilities (Fig. 4). In this context, high levels of fibulin-3 expressed and secreted by normal breast epithelial and pre-invasive ductal carcinoma in situ cells may function to inhibit the effects of TGF-β on the stroma in the early tumor microenvironment, with losses in expression during cancer progression promoting TGF-β signaling at the same time as the cancer cells become unresponsive via mutation or loss of receptor or Smad expression, increasing the tumor promoting effects of TGF-β signaling. This scenario is consistent with the role of enhanced TGF-β signaling in promoting tumor metastasis in the late stages of breast cancer. We provide preliminary evidence for epigenetic regulation mediating loss of fibulin-3, as has been reported in other tumor types[37, 47–49]. These results raise the exciting possibility that DNA methyltransferase inhibitors in clinical use could increase fibulin-3 levels and provide therapeutic benefit in this manner.

Our studies with conditioned media from breast cancer cells demonstrated a predominant effect on inhibiting TGF-β signaling, with more subtle effects on BMP-2 signaling (Fig. 1B), and no effects on BMP-9 signaling (Fig. 1C, Supplementary Figure 1B). However, in many cases we also observed an effect of conditioned media on increasing basal p-Smad2 levels (Fig. 1C, E, Supplementary Figure 1A). As the conditioned media contains secreted TGF-β

superfamily ligands, shed TGF-β superfamily receptors and other TGF-β superfamily activators and repressors, the observed effects of conditioned media may be due to the integrated effects of these components, in particular, TGF-β superfamily ligands that can stimulate Smad2 phosphorylation (i.e. activin and BMP). In addition to fibulin-3, we also identified another TGF-β regulator in the breast cancer conditioned media, βIGH3. Although its effects on TGF-β signaling were subtle, knockdown of βIGH3 suppressed TGF-β signaling, suggesting that it may function to promote TGF-β signaling. How the effects of the complex cancer microenvironment secretome are integrated to regulate cancer progression is currently being explored.

In summary, these studies provide a novel mechanism for how TGF-β signaling is regulated by the tumor microenvironment, and provide insight into targeting the TGF-β signaling pathway for the benefit of human cancer patients.

## Materials and Methods

### Cell Culture

MDA-MB-231 cells were from American Type Culture Collection (ATCC) and MDA-MB-231-4175 cells were acquired from Dr. Joan Massage at Memorial Sloan Kettering Cancer Institute and grown in MEM medium, supplemented with 10% fetal bovine serum (FBS), 5ml sodium pyruvate, and 5ml non-essential amino-acid. NMuMG cells were purchased from ATCC and grown in DMEM supplemented with 10% FBS and 10 μg/ml insulin. MCF-10A human breast cancer progression series of cell lines were acquired from Dr. William P. Schiemann at Case Western Reserve University and grown in DMEM/F12 medium, supplemented with 5% horse serum, 10 μg/ml insulin, 20 ng/ml EGF, 100 ng/ml hydrocortisone,100 ng/ml cholera toxin and 100 U/mL penicillin and 100 mg/mL streptomycin. 4T1 mouse breast cancer series of cell lines were acquired from Dr. William P. Schiemann at Case Western Reserve University and grown in DMEM, supplemented with 10% FBS. HMEC-1s were acquired from Dr. Edwin Edes at CDC and grown in MCDB-131 medium (Invitrogen), supplemented with 10% FBS, 1 μg/ml hydrocortisone (Sigma), 10 ng/ml EGF (Sigma) and 2 mM L-glutamine (Invitrogen). COS7 cells were purchased from ATCC and were grown in DMEM medium, supplemented with 10% fetal bovine serum. 18Co cells were from ATCC via Cell Culture Facility at Duke and grown in EMEM medium (Sigma), supplemented with 2mM glutamine, 1% NEAA and 10% FBS. EFEMP1 (Human) Recombinant Protein was purchased from Abnova.

### Spheroid-based sprout assay

Endothelial spheroids were prepared as previously reported[50]. Briefly, 1X103 HMEC-1 cells were cultured in hanging drops of 25 μl medium containing 20% methocel and 80% culture medium, and allowed to aggregate as spheroids. After 24h, the spheroids were collected using conditioned media from breast cancer cells and plated on 24-well plates coated with growth factor reduced Matrigel and treated as indicated. Sprouts were digitally imaged after the indicated times and the number and length of sprouts per spheroid quantitated.

### Transendothelial migration

$1 \times 10^5$ HMEC-1 cells were cultured on top of 24-well membrane of transwells until they formed a monolayer, and treated with conditioned media from breast cancer cells with or without 50 pM TGF-β1 for 12h. $1 \times 10^5$ GFP-labelled breast cancer cells were plated with serum free medium on the top of endothelial layers in a transwell. Media containing 0.5% BSA was placed in the lower chamber as a chemoattractant. Twenty-four hours later, the cells on the upper surface of the filter were removed by gently scrubbing with a cotton swab. Transendothelial migration of breast cancer cells was then assessed by fluorescent microscopy.

### Duolink assay

The Duolink assay (Olink Bioscience) was performed according to the manufacturer's protocol. Briefly, MDA-MB-231 cells were pretreated with breast cancer conditioned media or 200 ng/ml recombinant fibulin-3, and treated with 50 pM TGF-β1 for 10min. Cells were then washed with PBS, fixed with 4% paraformaldehyde, permeabilized in 0.1% Triton X-100/PBS for 5 min and then blocked with 5% bovine serum albumin in PBS for 1 h. Slides were incubated with anti-TβRI, and anti-TβRII (Santa Cruz Biotechnology, Inc) primary antibodies for 1hrs in room temperature and then incubated with PLA probe MINUS and PLUS mixture for 1h at 37°C. After ligation for 30min, and amplification for 100min at 37°C, the slides were labeled with DAPI, mounted with Prolong Anti-Fade (Sigma), digitally imaged and counted for number of the red dots per cells manually using ImageJ software.

### In vivo tumorigenicity and metastasis

MDA-MB-231-4175-Luc cells stably expressing firefly luciferase gene were infected with either an empty vector (EV) as control or fibulin-3 overexpression pBABE retrovirus, and stably infected cells were selected using 1 μg/ml puromycin for 72 hrs. EV and fibulin-3 overexpressing cells were implanted (50,000 cells/mouse) into the right-side inguinal mammary fat pads of female BALB/c mice. Starting from day 7, tumor growth and tumor metastasis were recorded by bioluminescence.

### Statistical analysis

Quantitative data are expressed as mean ± *SEM*. Statistical significance was determined by the two-tailed Student's t-test or one-way ANOVA, followed by the *LSD-t* test for multiple comparisons. A *P* value of less than 0.05 was considered statistically significant. To examine the statistical interaction between fibulin-3 expression and ligand treatment, 2-way ANOVA was performed with specific interest in the interaction term.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

## References

1. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. The Journal of clinical investigation. 2011; 121:3804–3809. [PubMed: 21965337]

2. Culig Z. Cytokine disbalance in common human cancers. Biochimica et biophysica acta. 2011; 1813:308–314. [PubMed: 21167870]

3. Hynes NE, Watson CJ. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harbor perspectives in biology. 2010; 2:a003186. [PubMed: 20554705]

4. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine & growth factor reviews. 2006; 17:325–337. [PubMed: 16931107]

5. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11:937s–943s. [PubMed: 15701890]

6. Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol. 2011; 3:a003277. [PubMed: 20810549]

7. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, et al. EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biological chemistry. 2009; 390:1293–1302. [PubMed: 19804359]

8. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992; 71:1003–1014. [PubMed: 1333888]

9. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. The Journal of biological chemistry. 1992; 267:5927–5930. [PubMed: 1556106]

10. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996; 85:947–950. [PubMed: 8674122]

11. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390:465–471. [PubMed: 9393997]

12. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends in biochemical sciences. 2000; 25:64–70. [PubMed: 10664585]

13. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell. 1998; 95:737–740. [PubMed: 9865691]

14. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425:577–584. [PubMed: 14534577]

15. Imamura T, Hikita A, Inoue Y. The roles of TGF-beta signaling in carcinogenesis and breast cancer metastasis. Breast cancer. 2012; 19:118–124. [PubMed: 22139728]

16. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, et al. Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell and tissue research. 2012; 347:73–84. [PubMed: 21845401]

17. Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. Journal of mammary gland biology and neoplasia. 2011; 16:97–108. [PubMed: 21494783]

18. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell cycle. 2009; 8:3319–3327. [PubMed: 19806012]

19. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast cancer research : BCR. 2011; 13:227. [PubMed: 22078026]

20. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer metastasis reviews. 2013; 32:303–315. [PubMed: 23114846]

21. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer cell. 2004; 6:17–32. [PubMed: 15261139]

22. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27:5904–5912. [PubMed: 18836471]

23. Buck MB, Knabbe C. TGF-beta signaling in breast cancer. Annals of the New York Academy of Sciences. 2006; 1089:119–126. [PubMed: 17261761]

24. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Critical reviews in oncogenesis. 1999; 10:303–360. [PubMed: 10654929]

25. Chang CF, Westbrook R, Ma J, Cao D. Transforming growth factor-beta signaling in breast cancer. Frontiers in bioscience : a journal and virtual library. 2007; 12:4393–4401. [PubMed: 17485383]

26. Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. The Journal of clinical investigation. 2013; 123:3925–3940. [PubMed: 23925295]

27. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, et al. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of clinical investigation. 2007; 117:206–217. [PubMed: 17160136]

28. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PloS one. 2013; 8:e84256. [PubMed: 24391924]

29. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. European journal of cancer. 2013; 49:1845–1859. [PubMed: 23453937]

30. Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. International journal of oncology. 2012; 40:130–138. [PubMed: 21904773]

31. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150:764–779. [PubMed: 22901808]

32. Gallagher WM, Currid CA, Whelan LC. Fibulins and cancer: friend or foe? Trends in molecular medicine. 2005; 11:336–340. [PubMed: 15961345]

33. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO reports. 2003; 4:1127–1131. [PubMed: 14647206]

34. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization The Journal of biological chemistry. 2007; 282:11805–11816. [PubMed: 17324935]

35. Luo R, Zhang M, Liu L, Lu S, Zhang CZ, Yun J. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PloS one. 2013; 8:e70511. [PubMed: 23936443]

36. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. International journal of cancer Journal international du cancer. 2009; 124:1727–1735. [PubMed: 19115204]

37. Tong JD, Jiao NL, Wang YX, Zhang YW, Han F. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma. 2011; 58:441–448. [PubMed: 21744999]

38. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011; 17:4523–4530. [PubMed: 21571867]

39. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, Fang FM, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. The Journal of pathology. 2010; 222:367–379. [PubMed: 20927779]

40. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer research. 2012; 72:3873–3885. [PubMed: 22665268]

41. Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z, et al. Fibulin-3 suppresses Wnt/beta-catenin signaling and lung cancer invasion. Carcinogenesis. 2014; 35:1707–1716. [PubMed: 24480807]

42. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998; 67:753–791. [PubMed: 9759503]

43. ten Dijke P, Miyazono K, Heldin CH. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Current opinion in cell biology. 1996; 8:139–145. [PubMed: 8791413]

44. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. The Journal of clinical investigation. 2003; 112:1116–1124. [PubMed: 14523048]

45. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436:518–524. [PubMed: 16049480]

46. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer research. 1992; 52:1399–1405. [PubMed: 1540948]

47. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. International journal of oncology. 2012; 40:402–408. [PubMed: 21901248]

48. Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J. CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathology oncology research : POR. 2012; 18:263–270. [PubMed: 21796503]

49. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. International journal of cancer Journal international du cancer. 2009; 124:1727–1735. [PubMed: 19115204]

50. Laib AM, Bartol A, Alajati A, Korff T, Weber H, Augustin HG. Spheroid-based human endothelial cell microvessel formation in vivo. Nature protocols. 2009; 4:1202–1215. [PubMed: 19644460]

**Fig. 1. Conditioned media from breast cancer cells inhibits TGF-β signaling**

(A, B) MDA-MB-231 cells were pretreated with conditioned media from MDA-MB-231 cells for 6 hrs, and then treated with 50 pM TGF-β1 (A) or 10 nM BMP2 (B) for 30min, and the cell lysates analyzed with the indicated antibodies. (C) HMEC-1 cells were pretreated with the conditioned media from MDA-MB-231 cells for 6 hrs, and then treated with 50 pM TGF-β1 or 2 ng/ml BMP9 for 30min, and the cell lysates analyzed with the indicated antibodies. (D) HMEC-1 cells were cultured in blank medium or in conditioned media from MDA-MB-231 cells for 3 hrs, treated with 50 pM TGF-β1 or 2 ng/ml BMP9 for 4 hrs, Smad7 and PAI-1 mRNA were measured using qRT-PCR. Quantitated data from 3 experiments +/− SEM were indicated. (E) HMEC-1 cells were pretreated with the indicated individual FPLC fractions for 6 hrs, and then treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. Results are representative of 3 independent experiments.

**Fig. 2. Fibulin-3 in conditioned media inhibits TGF-β signaling**

(A) MDA-MB-231 cells were cultured in blank medium or in conditioned media from shNTC- or shFBLN3-MDA-MB-231 cells for 6 hrs, treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. (B)(C) MDA-MB-231 cells were cultured in blank medium or in conditioned media from shNTC- or shFBLN3-MDA-MB-231 cells for 3 hrs, treated with 20 pM TGF-β1 for 4h, Smad7 (B) and PAI-1 (C) mRNA were measured using qRT-PCR. (D) HMEC-1 cells were cultured in blank medium or in conditioned media from shNTC- or shFBLN3-MDA-MB-231 cells for 6 hrs, and then treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. (E) HMEC-1 cells were pretreated with the MDA-MB-231 conditioned media which were immunodepleted with empty Protein A Sepharose (PAS) beads or fibulin-3 antibody (from Abcam) for 6 hrs, and then treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. (F) MDA-MB-231-4175 cells or (I) HMEC-1 cells were pretreated with the conditioned media from empty vector or fibulin-3 overexpressing MDA-MB-231-4175 cells for 6 hrs, and then treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. (G)(H) MDA-MB-231-4175 cells were pretreated with the conditioned media from empty vector or fibulin-3 overexpressing MDA-MB-231-4175 cells for 3 hrs, and then treated with 20 pM TGF-β1 for 4 hrs, Smad7 (G) and PAI-1 (H) mRNA were measured using qRT-PCR. (J) HMEC-1 cells were pretreated with indicated doses of purified fibulin-3 for 6 hrs, and then treated with 50 pM TGF-β1 for 30min, and the cell lysates analyzed with the indicated antibodies. Results are representative of 3 independent experiments. (K)(L) MDA-MB-231 cells were pretreated with 200 ng/ml purified fibulin-3 for 3 hrs, and then treated with 20 pM TGF-β1 for 2h, Smad7 (K) and PAI-1 (L) mRNA were measured using qRT-PCR.

**Fig. 3. Fibulin-3 inhibits TGF-β signaling through interaction with TβRI**

(A) MDA-MB-231 cells were either infected with ca-ALK5 adenovirus for 24 hrs, serum starved and treated with 200 ng/ml exogenous fibulin-3 for 6 hrs, or serum starved, pre-treated with 200 ng/ml exogenous fibulin-3 for 6 hrs, then treated with 50 pM TGF-β1 for 30 min, and the cell lysates analyzed with the indicated antibodies. (B) (C) Anti-Flag (B) or anti-HA (C) immunoprecipitate (IP) was prepared from COS7 cells expressing Flag-fibulin-3 and HA-TβRI or HATβRII. Flag-fibulin-3, HA-TβRI and HA-TβRII were detected in IP and total cell lysates by western blot analysis. (D) HA-TβRI or HA-TβRII were

immunoprecipitated in HA-TβRI or HA-TβRII overexpressing COS7 cells with anti-HA crosslinked beads, washed, incubate with 100 ng recombinant fibulin-3. Fibulin-3, HA-TβRI or HA-TβRII were detected by western blot analysis. (E) shNTC- or shFBLN3-MDA-MB-231 cells were pretreated with their conditioned media for 6 hrs respectively, and treated with 50 pM TGF-β1 for 10 min. Interaction between TβRI and TβRII was assessed by Duolink assay. Nuclei were stained using DAPI. Quantitated data were from 3 experiments +/− SEM. (F) MDA-MB-231 cells (left panel) or MDA-MB-231-4175 cells (right panel) were treated with 50 pM TGF-β1 for 12 hrs or 24 hrs. mRNA were extracted and converted to cDNA, and quantified using qRT-PCR. Quantitated data were from 3 or 4 experiments +/− SEM.

**(A)**



**(B)**



**(C)** TCGA Breast



**(D)** Curtis Breast



**(E)**



**(F)**



**(G)**



**(H)**



**Fig. 4. Fibulin-3 expression is decreased during breast cancer progression**
(A), (C) and (D) Analysis of publicly available microarray expression data for fibulin-3 mRNA expression in normal breast and breast cancer (A), in different types of breast cancer (C), and by breast cancer stage (D). (B) Representative sections of murine mammary epithelium and MDA-MB-231-4175 orthotopic tumor xenograft immunostained for fibulin-3. (E) Kaplan-Meier plot of survival based on low (below mean) or high (above mean) fibulin-3 expression. (F) Quantitative PCR analysis of fibulin-3 mRNA expression level in MCF10A breast cancer progression series. Results from three independent experiments were averaged and normalized relative to expression in MCF10A cells. (G) Conditioned media from MCF10A-CA1h and MCF10A-CA1a cells analyzed for fibulin-3 expression. (H) Quantitative PCR analysis of fibulin-3 mRNA expression level in MDA-MB-231 and MDA-MB-231-4175. Results from six independent experiments were averaged and normalized relative to expression in MDA-MB-231 cells.

**Fig. 5. Fibulin-3 inhibits TGF-β induced EMT, migration and invasion**

(A, B) MDA-MB-231 cells incubated with blank medium or with conditioned media from shNTC- and shFBLN3-MDA-MB-231 cells, were plated on non-coated (A) or Matrigel-coated (B) transwells, treated with or without 50 pM TGF-β1 and assessed for migration/invasion after 12 hrs. Quantitated data were from 3 experiments +/− SEM. (C) MDA-MB-231-4175 cells were incubated with blank medium or with conditioned media from empty vector or fibulin-3 stable overexpressing MDA-MB-231-4175 cells, plated on Matrigel-coated transwells, treated with or without 50 pM TGF-β1 and assessed for migration/invasion after 12 hrs. Quantitated data were from 3 experiments +/− SEM. (D) NMuMG cells were cultured in blank medium or in conditioned media from shNTC- or shFBLN3-NMuMG cells for 6 hrs, treated with 50 pM TGF-β for 30 min, and the cell lysates analyzed with the indicated antibodies. Quantitated data below were from 3 experiments +/− SEM. (E, F) NMuMG cells were cultured in regular medium or conditioned media from empty vector or fibulin-3 stable overexpressing NMUMG cells, treated with or without 50 pM TGF-β for 24 hrs, the cell morphology assessed by phase contrast

microscopy (E), and the cell lysates analyzed with the indicated antibodies (F). Fibulin-3 (G), ZO-1 (H), PAI-1 (I), and fibronectin (J) mRNA expression in 94 normal-tumor pairs from the TCGA dataset.

**Fig. 6. Loss of fibulin-3 enhances TGF-β induced transendothelial cell migration**

(A, B, C) HMEC-1 cells were cultured in hanging drops to make spheroids. Endothelial spheroids were seeded on Matrigel with conditioned media from empty vector or fibulin-3 stably overexpressing MDA-MB-231-4175 cells (A and B), or from shNTC-or shFBLN3-MDA-MB-231 cells (C), treated without or with 50 pM TGF-β1, and cultured overnight. The number of sprouts were counted and the length of every vessels were measured using Image J. Quantitated data were from 3 experiments +/− SEM. (D, E, F) A confluent endothelial monolayer growing in transwells was cultured in conditioned media from empty vector or fibulin-3 stably overexpressing MDA-MB-231-4175 cells (D and E), or from shNTC- and shFBLN3-MDA-MB-231 cells (F), treated without or with 50 pM TGF-β1 for 12 hrs. GFP labelled breast cancer cells were then plated on the top of transwell and allowed to migrate for 24 hrs, with the number of cells undergoing transendothelial cell migration (TEM) quantitated. Quantitated data were from 3 experiments +/− SEM.

**(A)**



**(B)** Two weeks after injection



**(C)**



**(D)**



Human vimentin staining

**(E)**



**(F)**



**(G)**



**(H)**



**Fig. 7. Fibulin-3 inhibits breast cancer EMT, invasiveness and metastasis *in vivo***

(A) MDA-MB-231-4175-vector (EV) or MDA-MB-231-4175-fibulin-3 cells (FBLN3) (50,000 cells/mouse) were implanted into the inguinal mammary fat pads of female nude mice. Primary tumor growth was recorded by measuring tumor size at 6 weeks after injection presented as mean ± SEM (A). Metastasis was followed by bioluminescence imaging every 7 postoperative days (POD) (B, C). (D) Tissue sections of liver from mice implanted with MDA-MB-231-4175-vector (EV) or MDA-MB-231-4175-fibulin-3 cells (FBLN3) were immunostained with anti-human vimentin antibody. (E, F) Primary tumors

from mice implanted with MDA-MB-231-4175-vector cells exhibiting local invasion (black arrows) of tumor cells into the adjacent smooth muscle layers (E) and mesenchymal morphology (F). (G, H) Tissue sections of primary tumors from mice implanted with MDA-MB-231-4175-vector (EV) or MDA-MB-231-4175-fibulin-3 cells (FBLN3) were immunostained for pan-cytokeratin (G, upper panel), fibronectin (G, bottom panel), p-Smad2 (H) and FBLN3 (H), respectively. Representative staining frequency and intensity is shown.

(A)



(B)

**Fig. 8. Fibulin-3-mediated regulation of TGF-β signaling and biology**
(A) TGF-β induces fibulin-3 expression and secretion. Fibulin-3 inhibits TGF-β signaling by interaction with TβRI, blocking complex formation with TβRII and downstream signaling. (B) Fibulin-3 expression decreases during breast cancer progression, with decreased fibulin-3 promoting TGF-β signaling in breast cancer cells and endothelial cells, and in turn promoting EMT, migration, invasion in breast cancer cells and endothelial permeability, collectively promoting metastasis.